Bax agonist, compositions, and methods related thereto
AssigneesEmory University, Board of Regents, The University of Texas System
InventorsXingming Deng, Jia ZHOU, Chunyong Ding
Life of this patent
Estimating the term…
Loading patent…
AssigneesEmory University, Board of Regents, The University of Texas System
InventorsXingming Deng, Jia ZHOU, Chunyong Ding
Estimating the term…
To compare sensitivities of the compounds, A549 human lung cancer cells were treated with increasing concentrations (0, 1, 5, 10, 25 μM) of 2-(2-Nitro-fluoren-9-ylidenemethyl)-phenol (CYD-1-87) and derivatives for 48 h. The surviving cell fraction was determined using the sulforhodamine B (SRB) assay as described in (Vichai & Kirtikara, Nat Protoc 1, 1112-1116, 2006 hereby incorporated by reference). The sulforhodamine B (SRB) assay is used for cell density determination, based on the measurement of cellular protein content. The method described here has been optimized for the toxicity screening of compounds to adherent cells in a 96-well format. After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base solution for OD determination at 510 nm using a microplate reader. The results are typically linear over a 20-fold range of cell numbers. CYD-2-11 has an IC50 of 1.93 μM, Derivative CYD-2-17 has an IC50 of 5.08 μM and CYD-2-13 has an IC50 of 5.91 μM. Data additional obtained from this assay is provided in FIG. 5. SMBA1 has an IC50 of 7.35 and CYD-4-61, 2-((3-((2-nitro-fluoren-9-ylidene)methyl)pyridin-2-yl)oxy)ethanamine has an IC50 of 0.026.
A method of treating lung cancer comprising administering an effective amount of a compound of Formula IB, to a subject in need thereof,
Dependencies are inferred from the claim text.